Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $8.83 Consensus PT from Analysts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has received an average rating of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.83.

A number of research firms recently weighed in on MRNS. StockNews.com upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. Truist Financial restated a “buy” rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Monday, September 23rd.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $1.78 on Monday. The stock has a market capitalization of $97.78 million, a P/E ratio of -0.67 and a beta of 1.14. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28. Marinus Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $11.26. The company’s fifty day moving average is $1.44 and its two-hundred day moving average is $2.36.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The firm had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. During the same quarter last year, the firm earned ($0.61) earnings per share. On average, sell-side analysts predict that Marinus Pharmaceuticals will post -1.88 earnings per share for the current year.

Institutional Trading of Marinus Pharmaceuticals

A number of large investors have recently made changes to their positions in MRNS. Point72 DIFC Ltd purchased a new position in Marinus Pharmaceuticals in the 2nd quarter valued at about $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $64,000. AQR Capital Management LLC lifted its stake in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $206,000. Finally, XTX Topco Ltd acquired a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $232,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.